ClinicalTrials.gg
TerminatedNCT03907202Updated Sep 3, 2020

A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

A Phase 1 interventional study of Daily injection of KBP/placebo for up to 28 days in Type II Diabetes Mellitus, sponsored by KeyBioscience AG. Terminated at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by KeyBioscience AG · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The trial was planned to be conducted in 4 cohorts but was terminated after completion of Cohort 2 for strategic reasons due to limited PD effects.

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.

Enrollment
607th of 688
25 · median 218
Started
2018
with 24 others
Phase 1
139 of 756
4 open now
Registered
563rd of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 607th largest by enrollment of the 688 interventional ones that give a count, is one of 25 that started in 2018, is one of 139 in phase 1, and was the 563rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, or all of them as a file.
02

Study summary

KeyBioscience is developing KBP-089, a dual activator of both the amylin and calcitonin receptors, for the treatment of type II diabetes mellitus, using a subcutaneous injectable mode of administration.

This is a double-blind, placebo-controlled, randomised, multiple-ascending dose phase I trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of KBP-089 in patients with type 2 diabetes, who are on stable therapy with metformin.

Subjects will receive daily subcutaneous injections in the abdomen over a period of 28 days. The planned maximum doses of KBP-089 to be investigated in the trial are 20 µg in cohort 1, 60 µg in cohort 2, and 150 µg in cohort 3. For cohort 1, the dose is planned to be escalated every 7 ±1 days, and for cohort 2 and cohort 3, every 3 days. Doses may be modified according to individual tolerability, but the dose regimen will not exceed 28 days.

The IMP is administered by daily subcutaneous injections taken in the morning before breakfast.

The trial is performed in Germany and at least 36 patients will be enrolled in the trial. The trial will be randomised 1:1:1 between maximum doses of KBP-089 of 20 µg, 60 µg, 150 µg and placebo. Within each of the three cohorts, 12 patients will be randomised 3:1 to KBP-089 and placebo.

03

Conditions studied

  • Type II Diabetes Mellitus

Keywords

  • Sub-cutaneous injection
  • Metformin
  • KBP-089
  • randomised
  • placebo-controlled
  • multiple-ascending dose
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the patient).
  • Male or female patient with T2DM.
  • Age between 18 and 64 years, both inclusive.
  • (BMI) >= 25.0 kg/m\^2.
  • >= 7 and \<=9.5%.
  • Stable therapy with metformin ± treatment with a second oral anti-diabetes drug (OAD) belonging to the class of dipeptidyl-peptidase 4 (DPP-4) inhibitors or sulfonylureas for at least 2 months prior to inclusion into the trial or not treated with glucose-lowering medications. Patients who are receiving stable treatment with a second OAD will be asked to discontinue the DPP-4 inhibitor or a sulfonylurea for at least 14 days prior the Initial Inpatient Dosing Visit.
  • Considered generally healthy (apart from T2DM) upon completion of medical history, physical examination, vital signs, and analysis of laboratory safety variables, as judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected or allergy to paracetamol or related products.
  • Prior treatment with a dual amylin and calcitonin receptor agonist (DACRA) or salmon calcitonin.
  • Receipt of any medicinal product in clinical development within 30 days or 5 half-lives of the medicinal product (whichever is longer) before randomisation in this trial.
  • History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  • Any history or presence of cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of conditions associated with diabetes mellitus), haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness as judged by the Investigator.
  • Medically unable or unwilling to discontinue current anti-diabetic therapy with DPP-4 inhibitor or sulfonylurea for at least 14 days prior to admission to the research facility (Day -2) and remain off medication until the follow-up visit. Patients taking metformin therapy at entry will continue their metformin at the usual individual dose throughout the trial.
  • Have had a significant change in weight, defined as a gain or loss of at least 5% body weight in the 3 months prior to screening.
  • A positive result in the alcohol and/or urine drug screen at the screening visit.
  • Positive to the screening test for Hepatitis Bs antigen () or antibodies and/or a positive result to the test for (HIV)-1/2 antibodies or HIV-1 antigen.
  • Have had a blood transfusion or severe blood loss within the past 6 months or have known hemoglobinopathy, hemolytic anemia, sickle cell anemia, or have a value \<11 g/dL (males) or \<10 g/dL (females), or any other condition known to interfere with methodology.
  • Blood donation or blood loss of more than 500 mL within the last 3 months or any blood donation within the last month prior to screening.
  • Females of .
  • Males with pregnant partners.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    KBP-089

    Three cohorts: * Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg * Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg * Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg

    Drug: Daily injection of KBP/placebo for up to 28 days

  • Placebo comparator
    Placebo

    For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.

    Drug: Daily injection of KBP/placebo for up to 28 days

Interventions

  • DrugDaily injection of KBP/placebo for up to 28 days

    Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs).

    All TEAEs will be coded using MedDRA and summarized by treatment and dose.

    Time frame: Day -1 to day 28

  2. Vital sign - Blood Pressure.

    Diastolic and systolic blood pressure (mmHg) are measured after at least 5 min rest in a supine position. Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.

    Time frame: Day -1 to day 28

  3. Vital sign - Pulse (beats per min).

    measured after at least 5 min rest in a supine position. Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.

    Time frame: Day -1 to day 28

  4. Vital sign - Body Temperature.

    Body temperature, tympanic (in Celcius). Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.

    Time frame: Day -1 to day 28

  5. Vital sign - Respiratory frequency.

    Respiratory frequency measured as breaths per min. Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.

    Time frame: Day -1 to day 28

  6. Electrocardiogram (ECG) - PQ interval.

    PQ interval (in msec) and any abnormality will be recorded and described in the CRF including the Investigator's assessment of clinical significance ('abnormal, not clinically significant' or 'abnormal, clinically significant').

    Time frame: Day -1 to day 28

  7. Electrocardiogram (ECG) - QRS complex.

    QRS interval (in msec) and any abnormality will be recorded and described in the CRF including the Investigator's assessment of clinical significance ('abnormal, not clinically significant' or 'abnormal, clinically significant').

    Time frame: Day -1 to day 28

  8. Electrocardiogram (ECG) - QT interval.

    QT interval (in msec) and any abnormality will be recorded and described in the CRF including the Investigator's assessment of clinical significance ('abnormal, not clinically significant' or 'abnormal, clinically significant').

    Time frame: Day -1 to day 28

  9. Safety laboratory parameter - lipids.

    Standard Lipid assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum). (Lipid parameters measured: Total cholesterol, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Triglycerides).

    Time frame: Day -1 to day 28

  10. Safety laboratory parameter - haematology.

    Standard Biochemistry assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum). (Haematology parameters measured: Haematocrit, Haemoglobin, Erythrocytes, Mean corpuscular volume (MCV), Mean corpuscular haemoglobin (MCH), Mean corpuscular haemoglobin concentration (MCHC), Thrombocytes (platelets), Leucocytes, Neutrophile granulocytes (total count and relative), Lymphocytes (total count and relative), Monocytes (total count and relative), Eosinophile granulocytes (total count and relative), Basophile granulocytes (total count and relative))

    Time frame: Day -1 to day 28

  11. Safety laboratory parameter - coagulation.

    Standard coagulation assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum). (coagulation parameters measured: International normalised ratio (INR), Activated partial thromboplastin time (APTT)

    Time frame: Day -1 to day 28

  12. Safety laboratory parameter - urinalysis.

    Standard Biochemistry assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum). (Urinalysis parameters measured: Protein, Glucose, Erythrocytes, Leucocytes, pH, Ketones)

    Time frame: Day -1 to day 28

Secondary outcomes

  1. Pharmacokinetic Evaluation - KBP-089 Area Under Curve.

    PK parameter (AUC 0-24) will be derived by non-compartmental analysis of the plasma concentration data for KBP-089

    Time frame: Day -1 to day 28

  2. Pharmacokinetic Evaluation - KBP-089 Cmax.

    PK parameter (Cmax) will be derived by non-compartmental analysis of the plasma concentration data for KBP-089

    Time frame: Day -1 to day 28

  3. Gastric emptying - Paracetamol Cmax.

    Gastric emptying is measured using paracetamol Cmax at baseline (Day -1), Day 1, and Day 28 for Cohorts 1 and 2 only

    Time frame: Day -1 to day 28

  4. Gastric emptying - Paracetamol Tmax.

    Gastric emptying is measured using paracetamol Tmax at baseline (Day -1), Day 1, and Day 28 for Cohorts 1 and 2 only

    Time frame: Day -1 to day 28

  5. Gastric emptying - Paracetamol Area Under Curve (AUC).

    Gastric emptying is measured using paracetamol AUC at baseline (Day -1), Day 1, and Day 28 for Cohorts 1 and 2 only

    Time frame: Day -1 to day 28

  6. Fasting and postprandial glucose concentration.

    Fasting and postprandial glucose following OGTT at baseline (Days -1) and Day 28

    Time frame: Day -1 to day 28

  7. Fasting and postprandial insulin concentration.

    Insulin following OGTT at baseline (Days -1) and Day 28

    Time frame: Day -1 to day 28

  8. Fasting and postprandial C-peptide concentration.

    Fasting and postprandial C-peptide following OGTT at baseline (Days -1) and Day 28

    Time frame: Day -1 to day 28

  9. Fasting and postprandial glucagon concentration.

    Fasting and postprandial glucagon following OGTT at baseline (Days -1) and Day 28

    Time frame: Day -1 to day 28

  10. Body weight.

    Body weight at Day -1 (baseline) and Day 28 (in kg)

    Time frame: Day -1 to day 28

  11. N-(1-deoxy)-fructosyl-haemoglobin (HbA1c).

    HbA1c at Day -1 (baseline) and Day 28 (in mmol/mol)

    Time frame: Day -1 to day 28

  12. Fridericia's corrected QT interval (QTcF).

    Fridericia's corrected QT interval (QTcF) at Day 1 and Day 27 (in msec)

    Time frame: Day 1 to day 27

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, D-41460, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Dec 2019, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2018
First posted
Apr 8, 2019
StartActual
Apr 17, 2018
Primary completionActual
Dec 3, 2019
CompletionActual
Dec 3, 2019
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03907202
Lead sponsor
KeyBioscience AG
Responsible party
Sponsor
First posted
Apr 8, 2019
Start date
Apr 17, 2018
Primary completion
Dec 3, 2019
Completion
Dec 3, 2019
Last update
Sep 3, 2020

Study contacts

Tim Heise, MD
principal investigator · Profil Institut für Stoffwechselforschung GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion